Genitourinary Cancer

2019

<

Cancer Programme

Group Leader

Josep Lloreta Trull

Prostate cancer is the most common non-cutaneous cancer in men, and urinary bladder cancer is the fourth most common overall in both sexes. In addition to their prevalence, there are specific features of their respective natural histories that make them two of the cancers that generate some of the highest economic costs and they are associated with high morbidity rates, thus both have a significant impact on patients’ quality of life and on health care costs.

These are two different models of carcinogenesis, reflecting diverse aspects of cancer biology. Two major pathways with different molecular, pathological and clinical profiles are well known in bladder cancer. A further advance relies on the identification of several specific molecular subclasses similar to those identified in breast cancer. Also in prostate cancer, the relatively unpredictable behavior of the disease appears to be related to different molecular subfamilies, namely, the complex subset of translocation-associated tumors, and the still poorly defined miscellaneous group of tumors not related to gene rearrangements.

Furthermore, in both tumors, it has been suggested that inflammatory and immunological responses may be involved in their initiation and progression and these are regarded as new avenues for therapeutic intervention. In both tumors, there is a high demand for markers of early diagnosis, follow-up, and response to therapy, as well as for new therapeutic targets and for parameters that allow a more personalized management of patients.

Our objectives are to identify genetic signatures that may be involved in the transition from a hypothetical latent phase to a clinically significant phase, as well as markers of progression and advanced disease, in order to better understand the natural history of bladder and prostatic carcinoma and to design adequate treatment strategies for early detection, monitoring, treatment stratification, and follow-up, tailored for the personalized management of each patient.

Research group

Members

Lluís Cecchini Rosell (Researcher)

Albert Francés Comalat (Researcher)

Lluís Fumadó Ciutat (Researcher)

Silvia Hernández Llodrà (Researcher)

Núria Juanpere Rodero (Researcher)

Glòria Nohales Taurines (Researcher)

Alejo Rodríguez-Vida Rodríguez (Researcher)

Marta Lorenzo Pérez (Technician)

Susana Pinó Donnay (Technician)

Laura Segalés Tañà (Technician)

Main PublicationsOngoing Research ProjectsClinical Trials Signed in 2019

Main Publications

• Powles T, Kockx M, Rodríguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25(11): 1706-1714. IF 30.641. D1.

• Castro E, Romero-Laorden N, del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, et al. (Rodríguez-Vida A) PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2019; 37(6): 490-503. IF 28.245. D1.

• Bellmunt J, Rodríguez-Vida A. Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncol 2019; 5(6): 904-905. IF 22.416. D1.

• Marin J, Dot I, Boguña M, Cecchini L, Zapatero A, Gracia-Arnillas MP, Pascual S, Vilà C, Castellví A, Pérez-Terán P, Gea J, Masclans JR. Structural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilation. Int Care Med 2019; 45(4): 488-500. IF 18.967. D1.

• Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, van Poppel H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur Urol 2019; 76(3): 368-380. IF 17.298. D1.

See all Publications

Ongoing Research Projects

• Validación clínica y mecanismos de acción de las alteraciones moleculares con valor predictivo de progresión en el cáncer de próstata: algoritmo molecular de la carcinogénesis prostática

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI15/00452)

- Period: from 2016 to 2019

- Principal investigator: Lloreta Trull, Josep

See all Projects

Clinical Trials Signed in 2019

• PROSTRATEGY: ensayo clínico aleatorizado, fase II/III, con múltiples brazos y multietapa, de estrategias de inmunoterapia en cáncer de próstata metastásico sensible a hormonas. Fase piloto

- Protocol: SOGUG-2016-A-IEC (PRO)-14

- Sponsor: Grupo Español de Oncología Genitourinaria (SOGUG)

- Budget: 12,000 €